Stock Analysis
Enzymatica Second Quarter 2024 Earnings: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023)
Enzymatica (STO:ENZY) Second Quarter 2024 Results
Key Financial Results
- Revenue: kr6.43m (down 27% from 2Q 2023).
- Net loss: kr13.8m (loss widened by 20% from 2Q 2023).
- kr0.08 loss per share (further deteriorated from kr0.07 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Enzymatica Earnings Insights
Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Sweden.
Performance of the Swedish Pharmaceuticals industry.
The company's shares are down 25% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 5 warning signs for Enzymatica you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Enzymatica is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether Enzymatica is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:ENZY
Enzymatica
A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.